Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Renal Denervation

FDA OKs Paradise Renal Denervation System for Hypertension

https://www.medscape.com/viewarticle/998237

- Company Press Release https://www.recormedical.com/recor-medical-and-otsuka-medical-devices-announce-first-fda-approved-renal-denervation-system-for-the-treatment-of-hypertension/

- Six-month Meta-analysis of RDN Studies https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066941

- March This Week in Cardiology with RDN Discussion https://www.medscape.com/viewarticle/989014

II. Potential Deadly Decisions in the ED

Even One Night in the ED Raises Risk for Death

https://www.medscape.com/viewarticle/998080

- JAMA Internal Medicine Study

III. Tirzepatide Approval

FDA Approves Tirzepatide for Treating Obesity

https://www.medscape.com/viewarticle/998225

- SURMOUNT 2 https://doi.org/10.1016/S0140-6736(23)01200-X

- SURMOUNT 1 https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

IV. AHA Preview

Mandrola's Top Trials to Look for at AHA 2023

https://www.medscape.com/viewarticle/998123

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]